Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...

The researchers conducted a retrospective analysis of costs associated with hospitalization of CLL patients with serious infections.

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

US FDA approves AstraZeneca’s Calquence plus venetoclax as first all-oral, fixed-duration combination for patients with CLL in the 1st-line setting: Cambridge, UK Monday, Februa ...

Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, ...

BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from ...

Accord Healthcare, Inc., a leading U.S. pharmaceutical company, today announced the launch of Lenalidomide Capsules in the United States, reinforcing the company's commitment to expanding access to ...

Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir ...

Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript February 4, 2026 Eli Lilly and Company beats earnings expectations. Reported EPS is $7.54, expectations were $6.91. Operator: Thanks ...